| Authors: |
Al-Sawaf O; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.; German CLL Study Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany., Locher BN; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Christen F; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Hablesreiter R; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Rajamani A; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.; German CLL Study Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany., Robrecht S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.; German CLL Study Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany., Zhang C; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.; German CLL Study Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany., Fink AM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.; German CLL Study Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany., Tausch E; Division of CLL, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany., Schneider C; Division of CLL, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany., Ritgen M; Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Kreuzer KA; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.; German CLL Study Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany., Kopp K; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Mertz ME; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Fustero-Torre C; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Kleo K; Department of Pathology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Seymour J; Peter MacCallum Cancer Center, Melbourne, Australia., Blombery P; Peter MacCallum Cancer Center, Melbourne, Australia., Bullinger L; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany., Chyla B; AbbVie Inc, North Chicago, IL., Jin HY; Genentech, Inc, South San Francisco, CA., Jiang Y; Genentech, Inc, South San Francisco, CA., Stilgenbauer S; Division of CLL, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany., Hallek M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.; German CLL Study Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany., Eichhorst B; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.; German CLL Study Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany., Langerbeins P; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.; German CLL Study Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany., Fischer K; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.; German CLL Study Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany., Damm F; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site, Berlin, Germany. |
